Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

The New England Journal of Medicine
Norwegian Multicenter Study Group

Abstract

A multicenter double-blind randomized study was carried out to compare the effect of timolol (10 mg twice daily) with that of placebo in patients surviving acute myocardial infarction. Treatment was started seven to 28 days after infarction in 1884 patients (945 taking timolol, and 939 placebo), who represented 52 per cent of those evaluated for entry; the patients were followed for 12 to 33 months (mean, 17). There were 152 deaths in the placebo group and 98 in the timolol group. When deaths that occurred during treatment or within 28 days of withdrawal were considered, the cumulated sudden-death rate over 33 months was 13.9 per cent in the placebo group and 7.7 per cent in the timolol group--a reduction of 44.6 per cent (P = 0.0001). The cumulated reinfarction rate was 20.1 per cent in the placebo group and 14.4 per cent in the timolol group (P = 0.0006). We conclude that long-term treatment with timolol in patients surviving acute myocardial infarction reduces mortality and the rate of reinfarction.

References

Feb 1, 1976·European Journal of Pharmacology·P MouilléE Gauter
Aug 1, 1978·Circulation·D G Shand, A J Wood
Jan 1, 1971·Circulation·O Paul, M Schatz
Jan 31, 1980·The New England Journal of Medicine·E Braunwald
May 3, 1980·British Medical Journal·J R Mitchell
Nov 1, 1962·British Heart Journal·A A PeelJ L Dall

❮ Previous
Next ❯

Citations

Sep 1, 1990·Clinical Cardiology·D MasselJ A Cairns
Nov 1, 1992·Clinical Cardiology·P Jain, S C Vlay
Mar 1, 1994·Clinical Cardiology·J A ReiffelR DiBianco
Nov 1, 1991·Journal of Clinical Pharmacology·N Z Kerin
Nov 1, 1991·Journal of Clinical Pharmacology·P J Podrid, T T Fuchs
Jul 1, 1992·Journal of Clinical Pharmacology·B J Materson, R A Preston
Mar 1, 1993·Journal of Clinical Pharmacology·S G Carruthers
Oct 1, 1996·Journal of Clinical Pharmacology·L M Prisant, G A Mensah
Sep 27, 2002·Statistics in Medicine·David L DeMets
Sep 27, 2002·Statistics in Medicine·J R Hampton
Sep 27, 2002·Statistics in Medicine·Robert Temple
Jan 1, 1997·Cardiovascular Drugs and Therapy·J R Hampton
Jan 1, 1988·European Journal of Clinical Pharmacology·K WintherE Eldrup
Jan 1, 1984·European Journal of Clinical Pharmacology·L A FerraraM Mancini
Jan 1, 1984·European Journal of Clinical Pharmacology·W SchiessR Gugler
Jan 1, 1987·European Journal of Clinical Pharmacology·G OlssonN Rehnqvist
Jan 1, 1983·European Journal of Clinical Pharmacology·A Leizorovicz, J P Boissel
Jan 1, 1983·European Journal of Clinical Pharmacology·B SilkeS H Taylor
Jan 1, 1985·European Journal of Clinical Pharmacology·S Johansen
Jan 1, 1988·Virchows Archiv. A, Pathological Anatomy and Histopathology·G GreveL Stangeland
Apr 1, 1995·Cardiovascular Drugs and Therapy·V PanfilovG Olsson
Jan 1, 1982·European Journal of Clinical Pharmacology·J A VedinC E Wilhelmsson
Jan 4, 1991·Klinische Wochenschrift·H PollakD Trubert-Exinger
Jun 1, 1990·Cardiovascular Drugs and Therapy·N Rehnqvist
Jul 1, 1990·Basic Research in Cardiology·W FlamengJ Vanhaecke
Jul 4, 1998·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·B Silke, J G Riddell
Nov 1, 1994·Journal of General Internal Medicine·S H SialJ S Goodwin
Dec 8, 2005·Current Heart Failure Reports·Kevin L Thomas, Eric J Velazquez
Sep 3, 2008·European Journal of Clinical Pharmacology·Juan Carlos Estrada, Dawood Darbar
Oct 17, 2012·Journal of General Internal Medicine·Mihaela S StefanPeter K Lindenauer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.